Uncategorized

Atara, Pierre Fabre’s cell therapy to get another shot at FDA approval

Published

on

There’s new life for a twice-rejected T cell therapy from Atara Biotherapeutics and Pierre Fabre Pharmaceuticals.

US regulators are willing to reconsider using a Phase 3 study as the basis for an approval, Atara said …

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version